ChemGenex to be acquired by Cephalon
29 March, 2011 by Tim DeanThe share price of Australian biopharma, ChemGenex (ASX:CXS), has soared following news that US-based Cephalon is making a bid to purchase the company.
Australia signs up to compulsory licensing of drugs for developing countries in need
25 March, 2011 by Tim DeanThe Australian Government has announced it will allow compulsory licensing of pharmaceuticals for export to developing countries in crisis under the WTO TRIPS Protocol.
Co-opting nature to make cheaper drugs
21 March, 2011 by Tim DeanAustralian scientists have developed a method for producing drugs that could combat cancer and other diseases by co-opting the natural machinery of sunflowers.
Glycomics could eliminate food poisoning from chicken
16 March, 2011 by Staff WritersA food additive for chickens developed using gylcomics could virtually eliminate the risk of getting food poisoning from raw chicken meat.
Clinuvel to begin trial of Scenesse in US and Europe
04 March, 2011 by Staff WritersPilot trials of Clinuvel’s skin repigmentation treatment, Scenesse (afamelanotide), will begin in the US and Europe to treat vitiligo.
Immuron granted patent for anti-influenza product
02 March, 2011 by Staff WritersAustralian patent issued for Imm-255, which is an orally administered anti-influenza candidate.
Bioscience boost at La Trobe
28 February, 2011 by Tim DeanThe $94 million La Trobe Institute of Molecular Science began construction last week and is set to open in 2012.
Living Cell Technologies and HealthLinx receive key patents
24 February, 2011 by Tim DeanLiving Cell Technologies (ASX:LCT) has received an Australian patent for its encapsulation technology, while HealthLinx (ASX:HTX) had its OvPlex diagnostic technology patented in the UK.
Sirtex posts strong 1H results
23 February, 2011 by Staff WritersSirtex Medical (ASX:SRX) posts $3.6 million profit on the back of increased sales in the face of currency bump.
QRxPharma completes phase III trial, prepares for NDA
21 February, 2011 by Tim DeanQRxPharma (ASX:QRX) will meet with the FDA for a pre-NDA meeting following positive results from pivotal phase III trial of MoxDuo.
Alexion acquires technology for MoCD therapy
14 February, 2011 by Staff WritersAlexion Pharmaceuticals has acquired patents and assets from German company, Orphatec Pharmaceuticals, for a therapy to treat molybdenum cofactor deficiency (MoCD) Type A.
Mesoblast issues $139 million in stock to Cephalon
14 February, 2011 by Tim DeanMesoblast to diversify product offerings with a $139 million cash injection from issuing a further 24.7 million shares to Cephalon.
Feature: Lab managers must take can-do attitude
14 February, 2011 by David BinningLab managers need to avoid being too risk averse when working to accommodate researchers’ needs.
New head of science at Australian Synchrotron talks life science research
10 February, 2011 by Tim DeanDr Andrew Peele, the new head of science for the Australian Synchrotron, talks about the road ahead for life sciences at the facility.
Immune system boosting hormone might lead to HIV cure
04 February, 2011 by Tim DeanResearchers have found that boosting the immune system cure chronic a viral infection in mice similar to HIV, opening up possible future therapies.
